nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K2—Sunitinib—kidney cancer	0.234	0.387	CbGbCtD
Trametinib—MAP2K1—Sunitinib—kidney cancer	0.234	0.387	CbGbCtD
Trametinib—CYP3A4—Everolimus—kidney cancer	0.0228	0.0378	CbGbCtD
Trametinib—CYP2C8—Pazopanib—kidney cancer	0.02	0.033	CbGbCtD
Trametinib—CYP3A4—Temsirolimus—kidney cancer	0.0154	0.0255	CbGbCtD
Trametinib—CYP2C8—Erlotinib—kidney cancer	0.0142	0.0236	CbGbCtD
Trametinib—CYP2C8—Paclitaxel—kidney cancer	0.013	0.0216	CbGbCtD
Trametinib—CYP2C8—Sorafenib—kidney cancer	0.0116	0.0192	CbGbCtD
Trametinib—CYP3A4—Pazopanib—kidney cancer	0.00809	0.0134	CbGbCtD
Trametinib—CYP3A4—Erlotinib—kidney cancer	0.00578	0.00956	CbGbCtD
Trametinib—CYP3A4—Paclitaxel—kidney cancer	0.00529	0.00875	CbGbCtD
Trametinib—CYP3A4—Sorafenib—kidney cancer	0.0047	0.00777	CbGbCtD
Trametinib—CYP3A4—Vinblastine—kidney cancer	0.00464	0.00768	CbGbCtD
Trametinib—CYP3A4—Vincristine—kidney cancer	0.00456	0.00755	CbGbCtD
Trametinib—CYP3A4—Sunitinib—kidney cancer	0.00381	0.0063	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—kidney cancer	0.00285	0.00472	CbGbCtD
Trametinib—MAP2K1—renal system—kidney cancer	0.0024	0.113	CbGeAlD
Trametinib—MAP2K1—kidney—kidney cancer	0.00232	0.109	CbGeAlD
Trametinib—MAP2K1—gonad—kidney cancer	0.00215	0.101	CbGeAlD
Trametinib—MAP2K2—renal system—kidney cancer	0.00211	0.0994	CbGeAlD
Trametinib—MAP2K2—kidney—kidney cancer	0.00204	0.0961	CbGeAlD
Trametinib—CYP3A4—urine—kidney cancer	0.00202	0.0953	CbGeAlD
Trametinib—MAP2K2—cortex of kidney—kidney cancer	0.00199	0.0936	CbGeAlD
Trametinib—MAP2K2—gonad—kidney cancer	0.00189	0.0892	CbGeAlD
Trametinib—MAP2K2—cardiac atrium—kidney cancer	0.00189	0.0891	CbGeAlD
Trametinib—CYP2C8—renal system—kidney cancer	0.000731	0.0344	CbGeAlD
Trametinib—CYP2C8—kidney—kidney cancer	0.000707	0.0333	CbGeAlD
Trametinib—CYP3A4—renal system—kidney cancer	0.000495	0.0233	CbGeAlD
Trametinib—CYP3A4—kidney—kidney cancer	0.000479	0.0226	CbGeAlD
Trametinib—Diarrhoea—Everolimus—kidney cancer	8.02e-05	0.000376	CcSEcCtD
Trametinib—Gastrointestinal pain—Sunitinib—kidney cancer	8.01e-05	0.000375	CcSEcCtD
Trametinib—Hyperhidrosis—Vincristine—kidney cancer	8.01e-05	0.000375	CcSEcCtD
Trametinib—Pruritus—Erlotinib—kidney cancer	8e-05	0.000375	CcSEcCtD
Trametinib—Fatigue—Dactinomycin—kidney cancer	7.99e-05	0.000374	CcSEcCtD
Trametinib—Epistaxis—Capecitabine—kidney cancer	7.98e-05	0.000374	CcSEcCtD
Trametinib—Dysgeusia—Paclitaxel—kidney cancer	7.89e-05	0.00037	CcSEcCtD
Trametinib—Oedema—Gemcitabine—kidney cancer	7.86e-05	0.000368	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—kidney cancer	7.81e-05	0.000366	CcSEcCtD
Trametinib—Infection—Gemcitabine—kidney cancer	7.81e-05	0.000366	CcSEcCtD
Trametinib—Back pain—Paclitaxel—kidney cancer	7.8e-05	0.000365	CcSEcCtD
Trametinib—Dizziness—Vinblastine—kidney cancer	7.78e-05	0.000364	CcSEcCtD
Trametinib—Dizziness—Everolimus—kidney cancer	7.75e-05	0.000363	CcSEcCtD
Trametinib—Muscle spasms—Paclitaxel—kidney cancer	7.75e-05	0.000363	CcSEcCtD
Trametinib—Abdominal pain—Sunitinib—kidney cancer	7.74e-05	0.000363	CcSEcCtD
Trametinib—Body temperature increased—Sunitinib—kidney cancer	7.74e-05	0.000363	CcSEcCtD
Trametinib—Diarrhoea—Erlotinib—kidney cancer	7.74e-05	0.000362	CcSEcCtD
Trametinib—Bradycardia—Capecitabine—kidney cancer	7.74e-05	0.000362	CcSEcCtD
Trametinib—Nervous system disorder—Gemcitabine—kidney cancer	7.71e-05	0.000361	CcSEcCtD
Trametinib—Thrombocytopenia—Gemcitabine—kidney cancer	7.69e-05	0.00036	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—kidney cancer	7.67e-05	0.000359	CcSEcCtD
Trametinib—Haemoglobin—Capecitabine—kidney cancer	7.64e-05	0.000358	CcSEcCtD
Trametinib—Skin disorder—Gemcitabine—kidney cancer	7.63e-05	0.000357	CcSEcCtD
Trametinib—Haemorrhage—Capecitabine—kidney cancer	7.6e-05	0.000356	CcSEcCtD
Trametinib—Vision blurred—Paclitaxel—kidney cancer	7.6e-05	0.000356	CcSEcCtD
Trametinib—Hyperhidrosis—Gemcitabine—kidney cancer	7.6e-05	0.000356	CcSEcCtD
Trametinib—Gastrointestinal pain—Dactinomycin—kidney cancer	7.58e-05	0.000355	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Vincristine—kidney cancer	7.55e-05	0.000353	CcSEcCtD
Trametinib—Urinary tract disorder—Capecitabine—kidney cancer	7.51e-05	0.000351	CcSEcCtD
Trametinib—Insomnia—Vincristine—kidney cancer	7.49e-05	0.000351	CcSEcCtD
Trametinib—Oedema peripheral—Capecitabine—kidney cancer	7.49e-05	0.000351	CcSEcCtD
Trametinib—Vomiting—Vinblastine—kidney cancer	7.48e-05	0.00035	CcSEcCtD
Trametinib—Dizziness—Erlotinib—kidney cancer	7.48e-05	0.00035	CcSEcCtD
Trametinib—Connective tissue disorder—Capecitabine—kidney cancer	7.47e-05	0.00035	CcSEcCtD
Trametinib—Vomiting—Everolimus—kidney cancer	7.46e-05	0.000349	CcSEcCtD
Trametinib—Anaemia—Paclitaxel—kidney cancer	7.45e-05	0.000349	CcSEcCtD
Trametinib—Urethral disorder—Capecitabine—kidney cancer	7.45e-05	0.000349	CcSEcCtD
Trametinib—Rash—Everolimus—kidney cancer	7.39e-05	0.000346	CcSEcCtD
Trametinib—Dermatitis—Everolimus—kidney cancer	7.39e-05	0.000346	CcSEcCtD
Trametinib—Headache—Vinblastine—kidney cancer	7.37e-05	0.000345	CcSEcCtD
Trametinib—Headache—Everolimus—kidney cancer	7.35e-05	0.000344	CcSEcCtD
Trametinib—Abdominal pain—Dactinomycin—kidney cancer	7.33e-05	0.000343	CcSEcCtD
Trametinib—Body temperature increased—Dactinomycin—kidney cancer	7.33e-05	0.000343	CcSEcCtD
Trametinib—Asthenia—Sorafenib—kidney cancer	7.3e-05	0.000342	CcSEcCtD
Trametinib—Leukopenia—Paclitaxel—kidney cancer	7.22e-05	0.000338	CcSEcCtD
Trametinib—Decreased appetite—Vincristine—kidney cancer	7.2e-05	0.000337	CcSEcCtD
Trametinib—Pruritus—Sorafenib—kidney cancer	7.2e-05	0.000337	CcSEcCtD
Trametinib—Vomiting—Erlotinib—kidney cancer	7.19e-05	0.000337	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	7.16e-05	0.000335	CcSEcCtD
Trametinib—Gastrointestinal disorder—Vincristine—kidney cancer	7.15e-05	0.000335	CcSEcCtD
Trametinib—Fatigue—Vincristine—kidney cancer	7.14e-05	0.000334	CcSEcCtD
Trametinib—Rash—Erlotinib—kidney cancer	7.13e-05	0.000334	CcSEcCtD
Trametinib—Dermatitis—Erlotinib—kidney cancer	7.13e-05	0.000334	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—kidney cancer	7.11e-05	0.000333	CcSEcCtD
Trametinib—Insomnia—Gemcitabine—kidney cancer	7.11e-05	0.000333	CcSEcCtD
Trametinib—Eye disorder—Capecitabine—kidney cancer	7.1e-05	0.000333	CcSEcCtD
Trametinib—Headache—Erlotinib—kidney cancer	7.09e-05	0.000332	CcSEcCtD
Trametinib—Constipation—Vincristine—kidney cancer	7.08e-05	0.000332	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—kidney cancer	7.08e-05	0.000332	CcSEcCtD
Trametinib—Cardiac disorder—Capecitabine—kidney cancer	7.05e-05	0.00033	CcSEcCtD
Trametinib—Cough—Paclitaxel—kidney cancer	7.03e-05	0.000329	CcSEcCtD
Trametinib—Asthenia—Sunitinib—kidney cancer	7.03e-05	0.000329	CcSEcCtD
Trametinib—Nausea—Vinblastine—kidney cancer	6.99e-05	0.000327	CcSEcCtD
Trametinib—Nausea—Everolimus—kidney cancer	6.96e-05	0.000326	CcSEcCtD
Trametinib—Diarrhoea—Sorafenib—kidney cancer	6.96e-05	0.000326	CcSEcCtD
Trametinib—Hypertension—Paclitaxel—kidney cancer	6.96e-05	0.000326	CcSEcCtD
Trametinib—Pruritus—Sunitinib—kidney cancer	6.93e-05	0.000324	CcSEcCtD
Trametinib—Angiopathy—Capecitabine—kidney cancer	6.9e-05	0.000323	CcSEcCtD
Trametinib—Myalgia—Paclitaxel—kidney cancer	6.86e-05	0.000321	CcSEcCtD
Trametinib—Arthralgia—Paclitaxel—kidney cancer	6.86e-05	0.000321	CcSEcCtD
Trametinib—Mediastinal disorder—Capecitabine—kidney cancer	6.85e-05	0.000321	CcSEcCtD
Trametinib—Decreased appetite—Gemcitabine—kidney cancer	6.83e-05	0.00032	CcSEcCtD
Trametinib—Chills—Capecitabine—kidney cancer	6.82e-05	0.000319	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	6.82e-05	0.000319	CcSEcCtD
Trametinib—Arrhythmia—Capecitabine—kidney cancer	6.79e-05	0.000318	CcSEcCtD
Trametinib—Gastrointestinal disorder—Gemcitabine—kidney cancer	6.78e-05	0.000318	CcSEcCtD
Trametinib—Fatigue—Gemcitabine—kidney cancer	6.78e-05	0.000317	CcSEcCtD
Trametinib—Gastrointestinal pain—Vincristine—kidney cancer	6.77e-05	0.000317	CcSEcCtD
Trametinib—Dizziness—Sorafenib—kidney cancer	6.73e-05	0.000315	CcSEcCtD
Trametinib—Constipation—Gemcitabine—kidney cancer	6.72e-05	0.000315	CcSEcCtD
Trametinib—Nausea—Erlotinib—kidney cancer	6.72e-05	0.000315	CcSEcCtD
Trametinib—Dry mouth—Paclitaxel—kidney cancer	6.71e-05	0.000314	CcSEcCtD
Trametinib—Diarrhoea—Sunitinib—kidney cancer	6.7e-05	0.000314	CcSEcCtD
Trametinib—Mental disorder—Capecitabine—kidney cancer	6.66e-05	0.000312	CcSEcCtD
Trametinib—Asthenia—Dactinomycin—kidney cancer	6.65e-05	0.000311	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—kidney cancer	6.63e-05	0.000311	CcSEcCtD
Trametinib—Erythema—Capecitabine—kidney cancer	6.62e-05	0.00031	CcSEcCtD
Trametinib—Malnutrition—Capecitabine—kidney cancer	6.62e-05	0.00031	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—kidney cancer	6.59e-05	0.000308	CcSEcCtD
Trametinib—Oedema—Paclitaxel—kidney cancer	6.58e-05	0.000308	CcSEcCtD
Trametinib—Abdominal pain—Vincristine—kidney cancer	6.55e-05	0.000307	CcSEcCtD
Trametinib—Body temperature increased—Vincristine—kidney cancer	6.55e-05	0.000307	CcSEcCtD
Trametinib—Infection—Paclitaxel—kidney cancer	6.54e-05	0.000306	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—kidney cancer	6.49e-05	0.000304	CcSEcCtD
Trametinib—Dysgeusia—Capecitabine—kidney cancer	6.48e-05	0.000303	CcSEcCtD
Trametinib—Dizziness—Sunitinib—kidney cancer	6.48e-05	0.000303	CcSEcCtD
Trametinib—Vomiting—Sorafenib—kidney cancer	6.47e-05	0.000303	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—kidney cancer	6.47e-05	0.000303	CcSEcCtD
Trametinib—Nervous system disorder—Paclitaxel—kidney cancer	6.45e-05	0.000302	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—kidney cancer	6.44e-05	0.000302	CcSEcCtD
Trametinib—Thrombocytopenia—Paclitaxel—kidney cancer	6.44e-05	0.000302	CcSEcCtD
Trametinib—Rash—Sorafenib—kidney cancer	6.42e-05	0.0003	CcSEcCtD
Trametinib—Dermatitis—Sorafenib—kidney cancer	6.41e-05	0.0003	CcSEcCtD
Trametinib—Back pain—Capecitabine—kidney cancer	6.4e-05	0.0003	CcSEcCtD
Trametinib—Skin disorder—Paclitaxel—kidney cancer	6.39e-05	0.000299	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	6.38e-05	0.000299	CcSEcCtD
Trametinib—Headache—Sorafenib—kidney cancer	6.38e-05	0.000299	CcSEcCtD
Trametinib—Muscle spasms—Capecitabine—kidney cancer	6.36e-05	0.000298	CcSEcCtD
Trametinib—Hyperhidrosis—Paclitaxel—kidney cancer	6.36e-05	0.000298	CcSEcCtD
Trametinib—Diarrhoea—Dactinomycin—kidney cancer	6.34e-05	0.000297	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	6.25e-05	0.000292	CcSEcCtD
Trametinib—Vision blurred—Capecitabine—kidney cancer	6.23e-05	0.000292	CcSEcCtD
Trametinib—Vomiting—Sunitinib—kidney cancer	6.23e-05	0.000292	CcSEcCtD
Trametinib—Body temperature increased—Gemcitabine—kidney cancer	6.21e-05	0.000291	CcSEcCtD
Trametinib—Rash—Sunitinib—kidney cancer	6.18e-05	0.000289	CcSEcCtD
Trametinib—Dermatitis—Sunitinib—kidney cancer	6.17e-05	0.000289	CcSEcCtD
Trametinib—Headache—Sunitinib—kidney cancer	6.14e-05	0.000287	CcSEcCtD
Trametinib—Anaemia—Capecitabine—kidney cancer	6.11e-05	0.000286	CcSEcCtD
Trametinib—Nausea—Sorafenib—kidney cancer	6.05e-05	0.000283	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—kidney cancer	6e-05	0.000281	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	5.99e-05	0.000281	CcSEcCtD
Trametinib—Insomnia—Paclitaxel—kidney cancer	5.95e-05	0.000279	CcSEcCtD
Trametinib—Asthenia—Vincristine—kidney cancer	5.94e-05	0.000278	CcSEcCtD
Trametinib—Leukopenia—Capecitabine—kidney cancer	5.92e-05	0.000277	CcSEcCtD
Trametinib—Vomiting—Dactinomycin—kidney cancer	5.89e-05	0.000276	CcSEcCtD
Trametinib—Rash—Dactinomycin—kidney cancer	5.85e-05	0.000274	CcSEcCtD
Trametinib—Nausea—Sunitinib—kidney cancer	5.82e-05	0.000272	CcSEcCtD
Trametinib—Cough—Capecitabine—kidney cancer	5.77e-05	0.00027	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—kidney cancer	5.72e-05	0.000268	CcSEcCtD
Trametinib—Decreased appetite—Paclitaxel—kidney cancer	5.72e-05	0.000268	CcSEcCtD
Trametinib—Hypertension—Capecitabine—kidney cancer	5.71e-05	0.000267	CcSEcCtD
Trametinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	5.68e-05	0.000266	CcSEcCtD
Trametinib—Fatigue—Paclitaxel—kidney cancer	5.67e-05	0.000266	CcSEcCtD
Trametinib—Diarrhoea—Vincristine—kidney cancer	5.67e-05	0.000265	CcSEcCtD
Trametinib—Asthenia—Gemcitabine—kidney cancer	5.64e-05	0.000264	CcSEcCtD
Trametinib—Myalgia—Capecitabine—kidney cancer	5.63e-05	0.000264	CcSEcCtD
Trametinib—Arthralgia—Capecitabine—kidney cancer	5.63e-05	0.000264	CcSEcCtD
Trametinib—Constipation—Paclitaxel—kidney cancer	5.63e-05	0.000263	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	5.59e-05	0.000262	CcSEcCtD
Trametinib—Pruritus—Gemcitabine—kidney cancer	5.56e-05	0.00026	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—kidney cancer	5.52e-05	0.000259	CcSEcCtD
Trametinib—Dry mouth—Capecitabine—kidney cancer	5.51e-05	0.000258	CcSEcCtD
Trametinib—Nausea—Dactinomycin—kidney cancer	5.51e-05	0.000258	CcSEcCtD
Trametinib—Dizziness—Vincristine—kidney cancer	5.48e-05	0.000256	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—kidney cancer	5.46e-05	0.000256	CcSEcCtD
Trametinib—Infestation—Doxorubicin—kidney cancer	5.46e-05	0.000256	CcSEcCtD
Trametinib—Oedema—Capecitabine—kidney cancer	5.4e-05	0.000253	CcSEcCtD
Trametinib—Gastrointestinal pain—Paclitaxel—kidney cancer	5.38e-05	0.000252	CcSEcCtD
Trametinib—Diarrhoea—Gemcitabine—kidney cancer	5.38e-05	0.000252	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—kidney cancer	5.36e-05	0.000251	CcSEcCtD
Trametinib—Infection—Capecitabine—kidney cancer	5.36e-05	0.000251	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—kidney cancer	5.32e-05	0.000249	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—kidney cancer	5.3e-05	0.000248	CcSEcCtD
Trametinib—Nervous system disorder—Capecitabine—kidney cancer	5.29e-05	0.000248	CcSEcCtD
Trametinib—Thrombocytopenia—Capecitabine—kidney cancer	5.29e-05	0.000248	CcSEcCtD
Trametinib—Vomiting—Vincristine—kidney cancer	5.27e-05	0.000247	CcSEcCtD
Trametinib—Skin disorder—Capecitabine—kidney cancer	5.24e-05	0.000246	CcSEcCtD
Trametinib—Rash—Vincristine—kidney cancer	5.22e-05	0.000245	CcSEcCtD
Trametinib—Hyperhidrosis—Capecitabine—kidney cancer	5.22e-05	0.000244	CcSEcCtD
Trametinib—Dermatitis—Vincristine—kidney cancer	5.22e-05	0.000244	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—kidney cancer	5.2e-05	0.000244	CcSEcCtD
Trametinib—Body temperature increased—Paclitaxel—kidney cancer	5.2e-05	0.000244	CcSEcCtD
Trametinib—Abdominal pain—Paclitaxel—kidney cancer	5.2e-05	0.000244	CcSEcCtD
Trametinib—Headache—Vincristine—kidney cancer	5.19e-05	0.000243	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—kidney cancer	5.15e-05	0.000241	CcSEcCtD
Trametinib—Vomiting—Gemcitabine—kidney cancer	5e-05	0.000234	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—kidney cancer	4.99e-05	0.000234	CcSEcCtD
Trametinib—Rash—Gemcitabine—kidney cancer	4.95e-05	0.000232	CcSEcCtD
Trametinib—Dermatitis—Gemcitabine—kidney cancer	4.95e-05	0.000232	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—kidney cancer	4.92e-05	0.000231	CcSEcCtD
Trametinib—Headache—Gemcitabine—kidney cancer	4.92e-05	0.000231	CcSEcCtD
Trametinib—Nausea—Vincristine—kidney cancer	4.92e-05	0.00023	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Capecitabine—kidney cancer	4.92e-05	0.00023	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—kidney cancer	4.9e-05	0.000229	CcSEcCtD
Trametinib—Insomnia—Capecitabine—kidney cancer	4.88e-05	0.000229	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—kidney cancer	4.84e-05	0.000227	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—kidney cancer	4.83e-05	0.000226	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—kidney cancer	4.81e-05	0.000225	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—kidney cancer	4.8e-05	0.000225	CcSEcCtD
Trametinib—Asthenia—Paclitaxel—kidney cancer	4.72e-05	0.000221	CcSEcCtD
Trametinib—Decreased appetite—Capecitabine—kidney cancer	4.69e-05	0.00022	CcSEcCtD
Trametinib—Nausea—Gemcitabine—kidney cancer	4.67e-05	0.000219	CcSEcCtD
Trametinib—Gastrointestinal disorder—Capecitabine—kidney cancer	4.66e-05	0.000218	CcSEcCtD
Trametinib—Fatigue—Capecitabine—kidney cancer	4.65e-05	0.000218	CcSEcCtD
Trametinib—Pruritus—Paclitaxel—kidney cancer	4.65e-05	0.000218	CcSEcCtD
Trametinib—Constipation—Capecitabine—kidney cancer	4.62e-05	0.000216	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—kidney cancer	4.58e-05	0.000214	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—kidney cancer	4.55e-05	0.000213	CcSEcCtD
Trametinib—Diarrhoea—Paclitaxel—kidney cancer	4.5e-05	0.000211	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—kidney cancer	4.44e-05	0.000208	CcSEcCtD
Trametinib—Gastrointestinal pain—Capecitabine—kidney cancer	4.42e-05	0.000207	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—kidney cancer	4.41e-05	0.000207	CcSEcCtD
Trametinib—Chills—Doxorubicin—kidney cancer	4.4e-05	0.000206	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—kidney cancer	4.38e-05	0.000205	CcSEcCtD
Trametinib—Dizziness—Paclitaxel—kidney cancer	4.35e-05	0.000204	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—kidney cancer	4.29e-05	0.000201	CcSEcCtD
Trametinib—Abdominal pain—Capecitabine—kidney cancer	4.27e-05	0.0002	CcSEcCtD
Trametinib—Body temperature increased—Capecitabine—kidney cancer	4.27e-05	0.0002	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—kidney cancer	4.26e-05	0.0002	CcSEcCtD
Trametinib—Erythema—Doxorubicin—kidney cancer	4.26e-05	0.0002	CcSEcCtD
Trametinib—Vomiting—Paclitaxel—kidney cancer	4.18e-05	0.000196	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—kidney cancer	4.18e-05	0.000196	CcSEcCtD
Trametinib—Rash—Paclitaxel—kidney cancer	4.15e-05	0.000194	CcSEcCtD
Trametinib—Dermatitis—Paclitaxel—kidney cancer	4.14e-05	0.000194	CcSEcCtD
Trametinib—Back pain—Doxorubicin—kidney cancer	4.12e-05	0.000193	CcSEcCtD
Trametinib—Headache—Paclitaxel—kidney cancer	4.12e-05	0.000193	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—kidney cancer	4.1e-05	0.000192	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—kidney cancer	4.02e-05	0.000188	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—kidney cancer	3.94e-05	0.000185	CcSEcCtD
Trametinib—Nausea—Paclitaxel—kidney cancer	3.91e-05	0.000183	CcSEcCtD
Trametinib—Asthenia—Capecitabine—kidney cancer	3.87e-05	0.000181	CcSEcCtD
Trametinib—Pruritus—Capecitabine—kidney cancer	3.82e-05	0.000179	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—kidney cancer	3.82e-05	0.000179	CcSEcCtD
Trametinib—Cough—Doxorubicin—kidney cancer	3.72e-05	0.000174	CcSEcCtD
Trametinib—Diarrhoea—Capecitabine—kidney cancer	3.69e-05	0.000173	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—kidney cancer	3.68e-05	0.000172	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—kidney cancer	3.63e-05	0.00017	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—kidney cancer	3.63e-05	0.00017	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	3.61e-05	0.000169	CcSEcCtD
Trametinib—Dizziness—Capecitabine—kidney cancer	3.57e-05	0.000167	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—kidney cancer	3.55e-05	0.000166	CcSEcCtD
Trametinib—Oedema—Doxorubicin—kidney cancer	3.48e-05	0.000163	CcSEcCtD
Trametinib—Infection—Doxorubicin—kidney cancer	3.46e-05	0.000162	CcSEcCtD
Trametinib—Vomiting—Capecitabine—kidney cancer	3.43e-05	0.000161	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—kidney cancer	3.41e-05	0.00016	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—kidney cancer	3.41e-05	0.00016	CcSEcCtD
Trametinib—Rash—Capecitabine—kidney cancer	3.4e-05	0.000159	CcSEcCtD
Trametinib—Dermatitis—Capecitabine—kidney cancer	3.4e-05	0.000159	CcSEcCtD
Trametinib—Headache—Capecitabine—kidney cancer	3.38e-05	0.000158	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—kidney cancer	3.38e-05	0.000158	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—kidney cancer	3.36e-05	0.000158	CcSEcCtD
Trametinib—Nausea—Capecitabine—kidney cancer	3.21e-05	0.00015	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.17e-05	0.000148	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—kidney cancer	3.15e-05	0.000147	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—kidney cancer	3.03e-05	0.000142	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	3e-05	0.000141	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—kidney cancer	3e-05	0.00014	CcSEcCtD
Trametinib—Constipation—Doxorubicin—kidney cancer	2.98e-05	0.000139	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—kidney cancer	2.85e-05	0.000133	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—kidney cancer	2.75e-05	0.000129	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—kidney cancer	2.75e-05	0.000129	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—kidney cancer	2.5e-05	0.000117	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—kidney cancer	2.46e-05	0.000115	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—kidney cancer	2.38e-05	0.000112	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—kidney cancer	2.3e-05	0.000108	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—kidney cancer	2.21e-05	0.000104	CcSEcCtD
Trametinib—Rash—Doxorubicin—kidney cancer	2.19e-05	0.000103	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—kidney cancer	2.19e-05	0.000103	CcSEcCtD
Trametinib—Headache—Doxorubicin—kidney cancer	2.18e-05	0.000102	CcSEcCtD
Trametinib—Nausea—Doxorubicin—kidney cancer	2.07e-05	9.68e-05	CcSEcCtD
Trametinib—MAP2K2—Disease—CDKN2B—kidney cancer	1.24e-05	7.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALDH1A1—kidney cancer	1.24e-05	7.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—KRAS—kidney cancer	1.23e-05	7.63e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ACY1—kidney cancer	1.22e-05	7.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNA1—kidney cancer	1.2e-05	7.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EIF4EBP1—kidney cancer	1.2e-05	7.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HSPB1—kidney cancer	1.2e-05	7.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—RAF1—kidney cancer	1.19e-05	7.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ANXA1—kidney cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PSMD7—kidney cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TSC1—kidney cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A3—kidney cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PGK1—kidney cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—RELA—kidney cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ERBB2—kidney cancer	1.18e-05	7.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD8A—kidney cancer	1.18e-05	7.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CTNNB1—kidney cancer	1.17e-05	7.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CDKN1B—kidney cancer	1.17e-05	7.27e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—LDHB—kidney cancer	1.17e-05	7.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MTOR—kidney cancer	1.17e-05	7.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD4—kidney cancer	1.16e-05	7.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN2B—kidney cancer	1.16e-05	7.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FLT1—kidney cancer	1.15e-05	7.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—JUN—kidney cancer	1.11e-05	6.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PSMD7—kidney cancer	1.11e-05	6.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ANXA1—kidney cancer	1.11e-05	6.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TSC1—kidney cancer	1.11e-05	6.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CTNNB1—kidney cancer	1.1e-05	6.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—kidney cancer	1.1e-05	6.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CDKN1B—kidney cancer	1.09e-05	6.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FLT1—kidney cancer	1.08e-05	6.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PTEN—kidney cancer	1.08e-05	6.69e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TSC2—kidney cancer	1.07e-05	6.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUNB—kidney cancer	1.07e-05	6.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PAK1—kidney cancer	1.07e-05	6.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MAPK3—kidney cancer	1.04e-05	6.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—JUN—kidney cancer	1.04e-05	6.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CTNNB1—kidney cancer	1.03e-05	6.42e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PDHB—kidney cancer	1.03e-05	6.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—kidney cancer	1.03e-05	6.4e-05	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—POMC—kidney cancer	1.03e-05	6.4e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CA9—kidney cancer	1.01e-05	6.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PTEN—kidney cancer	1.01e-05	6.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TSC2—kidney cancer	1e-05	6.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUNB—kidney cancer	9.99e-06	6.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PAK1—kidney cancer	9.99e-06	6.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HIF1A—kidney cancer	9.93e-06	6.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MAPK1—kidney cancer	9.91e-06	6.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TSC2—kidney cancer	9.9e-06	6.15e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	9.89e-06	6.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—POMC—kidney cancer	9.87e-06	6.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK3—kidney cancer	9.75e-06	6.06e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CCBL1—kidney cancer	9.72e-06	6.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KIT—kidney cancer	9.47e-06	5.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—kidney cancer	9.36e-06	5.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HIF1A—kidney cancer	9.29e-06	5.77e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK1—kidney cancer	9.27e-06	5.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TSC2—kidney cancer	9.27e-06	5.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—POMC—kidney cancer	9.23e-06	5.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK3—kidney cancer	9.2e-06	5.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KIT—kidney cancer	8.86e-06	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—kidney cancer	8.76e-06	5.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK1—kidney cancer	8.76e-06	5.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APC—kidney cancer	8.75e-06	5.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KIT—kidney cancer	8.75e-06	5.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF2—kidney cancer	8.73e-06	5.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—kidney cancer	8.72e-06	5.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN2B—kidney cancer	8.7e-06	5.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK3—kidney cancer	8.61e-06	5.35e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CRABP1—kidney cancer	8.6e-06	5.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1R—kidney cancer	8.44e-06	5.25e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GLIPR1—kidney cancer	8.43e-06	5.23e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPAT—kidney cancer	8.43e-06	5.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—kidney cancer	8.27e-06	5.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—BRAF—kidney cancer	8.22e-06	5.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK1—kidney cancer	8.19e-06	5.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APC—kidney cancer	8.18e-06	5.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KIT—kidney cancer	8.18e-06	5.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF2—kidney cancer	8.17e-06	5.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—kidney cancer	8.16e-06	5.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—RAF1—kidney cancer	8.14e-06	5.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN2B—kidney cancer	8.14e-06	5.05e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ITPR2—kidney cancer	8e-06	4.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1R—kidney cancer	7.9e-06	4.91e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APRT—kidney cancer	7.83e-06	4.87e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FH—kidney cancer	7.83e-06	4.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—kidney cancer	7.74e-06	4.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—BRAF—kidney cancer	7.69e-06	4.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—RAF1—kidney cancer	7.61e-06	4.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—kidney cancer	7.6e-06	4.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—RAF1—kidney cancer	7.43e-06	4.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—RELA—kidney cancer	7.4e-06	4.6e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.37e-06	4.58e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPC3—kidney cancer	7.36e-06	4.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB2—kidney cancer	7.36e-06	4.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—kidney cancer	7.3e-06	4.53e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ACHE—kidney cancer	7.29e-06	4.53e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTT1—kidney cancer	7.29e-06	4.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MTOR—kidney cancer	7.26e-06	4.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD4—kidney cancer	7.25e-06	4.5e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA2—kidney cancer	7.16e-06	4.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—kidney cancer	7.11e-06	4.42e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALAD—kidney cancer	6.98e-06	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—RAF1—kidney cancer	6.96e-06	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HIF1A—kidney cancer	6.95e-06	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TSC2—kidney cancer	6.93e-06	4.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—RELA—kidney cancer	6.93e-06	4.3e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SCARB1—kidney cancer	6.9e-06	4.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—kidney cancer	6.88e-06	4.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—RAF1—kidney cancer	6.86e-06	4.26e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS1—kidney cancer	6.83e-06	4.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—kidney cancer	6.83e-06	4.24e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.81e-06	4.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1B—kidney cancer	6.81e-06	4.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MTOR—kidney cancer	6.79e-06	4.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—kidney cancer	6.79e-06	4.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD4—kidney cancer	6.78e-06	4.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTOR—kidney cancer	6.7e-06	4.16e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PSMD7—kidney cancer	6.7e-06	4.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—kidney cancer	6.69e-06	4.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—kidney cancer	6.67e-06	4.14e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.66e-06	4.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—kidney cancer	6.65e-06	4.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—kidney cancer	6.64e-06	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIF1A—kidney cancer	6.5e-06	4.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TSC2—kidney cancer	6.49e-06	4.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—JUN—kidney cancer	6.48e-06	4.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—kidney cancer	6.44e-06	4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—RAF1—kidney cancer	6.42e-06	3.99e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.39e-06	3.97e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PGK1—kidney cancer	6.39e-06	3.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1B—kidney cancer	6.37e-06	3.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—kidney cancer	6.35e-06	3.95e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—BCHE—kidney cancer	6.35e-06	3.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1B—kidney cancer	6.29e-06	3.91e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A5—kidney cancer	6.27e-06	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—kidney cancer	6.27e-06	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTOR—kidney cancer	6.27e-06	3.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LDHB—kidney cancer	6.26e-06	3.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—kidney cancer	6.26e-06	3.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—kidney cancer	6.24e-06	3.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—kidney cancer	6.22e-06	3.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—kidney cancer	6.21e-06	3.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—kidney cancer	6.12e-06	3.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—kidney cancer	6.12e-06	3.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—kidney cancer	6.07e-06	3.77e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC2A1—kidney cancer	6.06e-06	3.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—kidney cancer	6.02e-06	3.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—kidney cancer	5.94e-06	3.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—kidney cancer	5.88e-06	3.66e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.88e-06	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—kidney cancer	5.87e-06	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—kidney cancer	5.87e-06	3.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—POMC—kidney cancer	5.83e-06	3.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—kidney cancer	5.79e-06	3.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—kidney cancer	5.76e-06	3.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—kidney cancer	5.73e-06	3.56e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—kidney cancer	5.73e-06	3.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK1—kidney cancer	5.58e-06	3.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—kidney cancer	5.56e-06	3.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—kidney cancer	5.49e-06	3.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—POMC—kidney cancer	5.45e-06	3.39e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA9—kidney cancer	5.43e-06	3.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—kidney cancer	5.42e-06	3.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—kidney cancer	5.39e-06	3.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—kidney cancer	5.36e-06	3.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—kidney cancer	5.27e-06	3.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK1—kidney cancer	5.22e-06	3.24e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.13e-06	3.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK1—kidney cancer	5.1e-06	3.17e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—kidney cancer	5.05e-06	3.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—kidney cancer	5.01e-06	3.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—kidney cancer	4.95e-06	3.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—kidney cancer	4.93e-06	3.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—kidney cancer	4.84e-06	3.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—kidney cancer	4.82e-06	2.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—kidney cancer	4.81e-06	2.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAF1—kidney cancer	4.81e-06	2.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RELA—kidney cancer	4.79e-06	2.97e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—kidney cancer	4.78e-06	2.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK1—kidney cancer	4.77e-06	2.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—kidney cancer	4.76e-06	2.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK1—kidney cancer	4.71e-06	2.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTOR—kidney cancer	4.69e-06	2.92e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—kidney cancer	4.64e-06	2.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—kidney cancer	4.63e-06	2.88e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CRABP1—kidney cancer	4.62e-06	2.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—kidney cancer	4.53e-06	2.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—kidney cancer	4.51e-06	2.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—kidney cancer	4.5e-06	2.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAF1—kidney cancer	4.5e-06	2.79e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RELA—kidney cancer	4.48e-06	2.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—kidney cancer	4.45e-06	2.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—kidney cancer	4.45e-06	2.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—kidney cancer	4.42e-06	2.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK1—kidney cancer	4.4e-06	2.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—kidney cancer	4.4e-06	2.74e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—kidney cancer	4.4e-06	2.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTOR—kidney cancer	4.39e-06	2.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—kidney cancer	4.31e-06	2.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ITPR2—kidney cancer	4.29e-06	2.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—kidney cancer	4.2e-06	2.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—kidney cancer	4.19e-06	2.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—kidney cancer	4.16e-06	2.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—kidney cancer	4.16e-06	2.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—kidney cancer	4.14e-06	2.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—kidney cancer	4.12e-06	2.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—kidney cancer	4.09e-06	2.54e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—kidney cancer	4.06e-06	2.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—kidney cancer	4.03e-06	2.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—kidney cancer	3.93e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—kidney cancer	3.92e-06	2.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ACHE—kidney cancer	3.91e-06	2.43e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—kidney cancer	3.91e-06	2.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—kidney cancer	3.89e-06	2.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—kidney cancer	3.82e-06	2.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—kidney cancer	3.79e-06	2.36e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SCARB1—kidney cancer	3.7e-06	2.3e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS1—kidney cancer	3.67e-06	2.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—kidney cancer	3.66e-06	2.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.62e-06	2.25e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PSMD7—kidney cancer	3.6e-06	2.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—kidney cancer	3.47e-06	2.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—kidney cancer	3.43e-06	2.13e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BCHE—kidney cancer	3.41e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—kidney cancer	3.37e-06	2.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.37e-06	2.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK1—kidney cancer	3.3e-06	2.05e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—POMC—kidney cancer	3.28e-06	2.04e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.25e-06	2.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—kidney cancer	3.24e-06	2.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—kidney cancer	3.15e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—kidney cancer	3.11e-06	1.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK1—kidney cancer	3.08e-06	1.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—kidney cancer	2.91e-06	1.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—kidney cancer	2.86e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—kidney cancer	2.77e-06	1.72e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—kidney cancer	2.71e-06	1.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—kidney cancer	2.68e-06	1.66e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—kidney cancer	2.62e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—kidney cancer	2.59e-06	1.61e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—kidney cancer	2.57e-06	1.6e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—kidney cancer	2.49e-06	1.55e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.36e-06	1.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—kidney cancer	2.28e-06	1.42e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—POMC—kidney cancer	1.76e-06	1.09e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.61e-06	1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—kidney cancer	1.41e-06	8.73e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—kidney cancer	1.23e-06	7.61e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.65e-07	5.37e-06	CbGpPWpGaD
